UPDATE: Bed Bath & Beyond (BBBY) PT Raised to $22 at UBS

Bed Bath & Beyond (BBBY) PT Lowered to $22 as KeyBanc Expects Continued Underperformance

April 15, 2021 7:12 AM EDT

KeyBanc analyst Bradley Thomas lowered the price target on Bed Bath & Beyond (NASDAQ: BBBY) to $22.00 (from $24.00) while maintaining a Underweight rating after the company reported 4Q adjusted EPS of $0.40, above the consensus of $0.31, driven primarily by a greater than expected decrease in SG&A expenses. Total enterprise sales... More

Bed Bath & Beyond (BBBY) PT Lowered to $27 at Wedbush

April 15, 2021 6:40 AM EDT

Wedbush analyst Seth Basham lowered the price target on Bed Bath & Beyond (NASDAQ: BBBY) to $27.00 (from $33.00) while maintaining a Neutral rating.... More

Baird Reiterates Neutral Rating on Bed Bath & Beyond (BBBY), Will Monitor Turnaround Story

April 15, 2021 6:27 AM EDT

Baird analyst Peter S. Benedict reiterated a Neutral on Bed Bath & Beyond (NASDAQ: BBBY)

The analyst comments "4Q results were better than expected, and FY21 guidance was reiterated. That said, 1Q's adjusted EBITDA outlook was light, and store traffic/comps remain under... More

Bed Bath & Beyond (BBBY) PT Lowered to $30 at Telsey

April 15, 2021 5:19 AM EDT

Telsey analyst Cristina Fernandez lowered the price target on Bed Bath & Beyond (NASDAQ: BBBY) to $30.00 (from $40.00) while maintaining a Market Perform rating.... More

Increasing unusual put option volume: ERIC BBBY

April 14, 2021 10:33 AM EDT

Increasing unusual put option volume: ERIC BBBY

... More

Pre-Open Stock Movers 04/14: (GALT) (MBRX) (IDEX) Higher; (BBBY) (MFH) (DISCK) Lower (more...)

April 14, 2021 9:23 AM EDT

Today's Pre-Open Stock Movers:

Galectin Therapeutics Inc. (NASDAQ: GALT) 33% HIGHER; announced that a paper published in the peer-reviewed Journal for ImmunoTherapy of Cancer (JITC), the highest ranked fully open access immunology journal, provides further clinical evidence that using belapectin, a potent galectin-3 inhibitor, in combination with pembrolizumab (KEYTRUDA®), a PD-1 inhibitor, significantly enhances tumor response to immunotherapy in patients with advanced metastatic melanoma (MM) and head and neck squamous cell carcinoma (HNSCC).

Bed Bath & Beyond (NASDAQ: BBBY) 11.2%... More

Bed Bath & Beyond (BBBY) Tops Q4 EPS by 9c, Reaffirms Outlook

April 14, 2021 7:02 AM EDT

Bed Bath & Beyond (NASDAQ: BBBY) reported Q4 EPS of $0.40, $0.09 better than the analyst estimate of $0.31. Revenue for the quarter came in at $2.62 billion versus the consensus estimate of $2.63 billion.

3rd Consecutive Quarter of Comparable Sales Growth+4% Comp Sales growth on Total Enterprise, including digital comp growth of... More

Bed Bath & Beyond (BBBY) call put ratio 1 call to 1.5 puts into quarter release and outlook

April 13, 2021 3:53 PM EDT

Bed Bath & Beyond (NASDAQ: BBBY) call put ratio 1 call to 1.5 puts into quarter release and outlook

... More